Literature DB >> 6381871

Counterregulatory hormone release after human and porcine insulin in healthy subjects and patients with pituitary disorders.

M M Landgraf-Leurs, I Brügelmann, S Kammerer, R Lorenz, R Landgraf.   

Abstract

Human and porcine insulin were administered intravenously to a group of healthy volunteers in two different doses (0.075 IU/kg body weight and 0.12 IU/kg body weight) and to two groups of randomly selected patients with pituitary disorders in a dose adapted to their individual glucose tolerance (0.12-0.17 IU/kg body weight for porcine and 0.15-0.18 IU/kg body weight for human insulin). The blood glucose and potassium lowering effect, the feedback regulation of endogenous insulin release, and the liberation of the counterregulatory hormones glucagon, cortisol, adrenocorticotropic hormone (ACTH), prolactin (hPRL), human growth hormone (hGH), and catecholamines were measured before and after injection of human or porcine insulin. The maximal effect, the area under the concentration-time curve, the percentage effect, and the increase above baseline for the two doses of insulin and the two types of insulin were compared. There were no significant differences in the calculated parameters between the two insulin types at the same doses except with prolactin. At 0.075 IU/kg human insulin induced significantly less prolactin release than porcine insulin. Comparing the two doses of the same insulin serum insulin levels, blood glucose, glucagon, norepinephrine, and prolactin were lower at the low dose of each insulin. In addition ACTH and epinephrine were also lower after human insulin at 0.075 IU/kg. The subjective signs of hypoglycemia were less pronounced after human insulin. It is concluded that the biological effects of human insulin are comparable to porcine insulin although prolactin release is significantly reduced after human insulin. If this difference is an indication of different receptor sensitivities for human and porcine insulin in the central nervous system and if the diminished signs of hypoglycemia are a consequence of this, then further studies are required.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381871     DOI: 10.1007/bf01716462

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  25 in total

1.  [Enzymatic determination of glucose and fructose simultaneously].

Authors:  F H SCHMIDT
Journal:  Klin Wochenschr       Date:  1961-12-01

Review 2.  Glucose counterregulation in man.

Authors:  P E Cryer
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

3.  Does insulin play a role in the regulation of its own secretion?

Authors:  W Beischer; M Schmid; W Kerner; L Keller; E F Pfeiffer
Journal:  Horm Metab Res       Date:  1978-03       Impact factor: 2.936

4.  Symposium on biosynthetic human insulin.

Authors: 
Journal:  Diabetes Care       Date:  1981 Mar-Apr       Impact factor: 19.112

5.  Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones.

Authors:  G Boden; G A Reichard; R D Hoeldtke; I Rezvani; O E Owen
Journal:  N Engl J Med       Date:  1981-11-12       Impact factor: 91.245

6.  Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man.

Authors:  C Rosak; P H Althoff; F Enzmann; K Schöffling
Journal:  Diabetes Care       Date:  1982 Nov-Dec       Impact factor: 19.112

7.  Chemical, physical, and biologic properties of biosynthetic human insulin.

Authors:  R E Chance; E P Kroeff; J A Hoffmann; B H Frank
Journal:  Diabetes Care       Date:  1981 Mar-Apr       Impact factor: 19.112

8.  Comparison of potency of porcine insulin and semisynthetic human insulin at 3 dose levels using the euglycaemic clamp.

Authors:  D J Chisholm; E W Kraegen; M J Hewett; L Lazarus
Journal:  Horm Metab Res       Date:  1983-09       Impact factor: 2.936

9.  Lack of glucagon response in glucose counter-regulation in type 1 (insulin-dependent) diabetics: absence of recovery after prolonged optimal insulin therapy.

Authors:  G Bolli; G Calabrese; P De Feo; P Compagnucci; G Zega; G Angeletti; M G Cartechini; F Santeusanio; P Brunetti
Journal:  Diabetologia       Date:  1982-02       Impact factor: 10.122

10.  Prolactin: a diabetogenic hormone.

Authors:  R Landgraf; M M Landraf-Leurs; A Weissmann; R Hörl; K von Werder; P C Scriba
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

View more
  3 in total

1.  Human insulin and unawareness of hypoglycaemia: need for a large randomised trial.

Authors:  M Egger; G D Smith; A Teuscher
Journal:  BMJ       Date:  1992-08-08

2.  Human insulin.

Authors:  R B Tattersall; I A Macdonald
Journal:  BMJ       Date:  1989-11-25

3.  Human insulin: much ado about hypoglycaemia (un)awareness.

Authors:  M Berger
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.